First publicly listed company to actively investigate psilocybin’s potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the launch of a new psilocybin longevity research initiative in collaboration with leading researchers in South Africa. This program positions Psyence BioMed as t ...

Birmingham, Alabama, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Curaechoice, the nation’s #1 leader in No-Cost Benefits Optimization Solutions, announced today that it has selected CVS Caremark at its pharmacy benefit manager (PBM), This milestone represents Curaechoice’s mission and commitment to reducing prescription drug costs.  Curaechoice members and their families will be able to fill prescriptions through CVS Caremark’s nationwide network of 65,000 pharmacies and retail and mail-order channels beginning Janua ...

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Mobile-Network Solutions (MNDR) is up 96% at $3.26 - PACS Group, Inc. (PACS) is up 44% at $24.37 - Cerence Inc. (CRNC) is up 28% at $10.16 - Magnera Corporation (MAGN) is up 26% at $10.07 - Oddity Tech Ltd. (ODD) is up 17% at $43.75 - Allot Ltd. (ALLT) is up 14% at $9.80 - Artiva Biotherapeutics, Inc. (ARTV) is up 14% at $3.88 - Kulicke and Soffa Industries, Inc. (KLIC) is up 13% at $40.22 - Fossil Group, Inc. (FOSL) is up 12% at $2.29 - NVIDIA Corporation (NVDA) is up 5% at $195.84 [3] Premarket Losers - Brera Holdings PLC (SLMT) is down 33% at $3.84 - Bath & Body Works, Inc. (BBWI) is down 14% at $18.04 - Cemtrex, Inc. (CETX) is down 11% at $3.20 - Atkore Inc. (ATKR) is down 9% at $60.00 - Gloo Holdings, Inc. (GLOO) is down 9% at $7.30 - SMX (Security Matters) Public Limited Company (SMX) is down 9% at $4.60 - Sonim Technologies, Inc. (SONM) is down 8% at $7.31 - Psyence Biomedical Ltd. (PBM) is down 7% at $2.56 - MMTec, Inc. (MTC) is down 6% at $2.00 - Ridgetech, Inc. (RDGT) is down 5% at $4.78 [4]

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs. This is a significant achievement for the Company as it prepa ...

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Psyence BioMed (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that, through its strategic investment in PsyLabs, it is now the only publicly listed psychedelics company with active operations and manufacturing capabilities based in Africa – the natural and original source of ibogaine. Derived from the Tabernanthe iboga shrub nat ...

Core Insights - Psyence Biomedical Ltd. has achieved a significant clinical milestone by successfully dosing multiple patients in its Phase IIb clinical trial for nature-derived psilocybin as a treatment for Adjustment Disorder in palliative care [1][2][5] Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, particularly in palliative care [7] - The company is recognized as a global leader in late-stage psychedelic drug development and is the first life sciences biotechnology company specializing in this area to be listed on Nasdaq [2][7] Clinical Trial Details - The Phase IIb study is designed to meet regulatory expectations and includes a larger sample size, rigorous randomization, and a multi-site structure to enhance data reliability and generalizability [3][5] - The trial aims to enroll 87 patients across Australia, with participants receiving either 10 mg or 25 mg of psilocybin or a low-dose comparator of 1 mg, alongside structured psychotherapy [5] - The study will assess the efficacy, safety, and durability of response to psilocybin as a potential first-in-class treatment for Adjustment Disorder in palliative care settings [5][6] Operational Readiness - Patients have been dosed at two active clinical sites in Australia, with plans to expand to a third site to accelerate data collection, with topline results expected by the end of 2026 [4][6] - The operational readiness and recruitment efficiency of the company have been highlighted as key strengths in executing the trial [4][6]

Core Insights - Psyence Biomedical Ltd. has made a follow-on investment of USD 3,500,000 in PsyLabs, enhancing its supply chain for psychedelic compounds [1][2] - This investment follows a previous investment of USD 500,000 in April 2025, indicating a strong commitment to securing high-quality, GMP-grade psychedelic ingredients [2][3] - The CEO of Psyence BioMed emphasized the strategic importance of this investment in building a fully integrated company focused on sustainable and scalable production [3] Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company specializing in nature-derived psilocybin and ibogaine therapies aimed at addressing unmet mental health needs [7] - It is the first life sciences biotechnology company focused on developing non-synthetic psychedelic medicine to be listed on Nasdaq [7] - The company aims to create safe, effective, and FDA-approved treatments for a range of mental health disorders [7] Partnership and Production - PsyLabs is recognized as a leading producer of purified psychedelic active pharmaceutical ingredients (APIs) and is federally licensed to cultivate and export various psychedelic compounds [9] - The partnership between Psyence BioMed and PsyLabs is strengthened through this investment, positioning Psyence as a leader in the emerging psychedelic therapeutics sector [5] - PsyLabs operates a state-of-the-art facility in Southern Africa, utilizing the region's botanical heritage under strict ethical and sustainable practices [4][10] Strategic Goals - The investment aims to secure a reliable supply of premium psychedelic compounds for Psyence BioMed's clinical research programs, ensuring long-term value for investors [2][3] - The company is focused on building a responsible global supply chain, which is crucial for advancing its clinical pipeline and commercial opportunities [3][5]

Group 1: Super League Enterprise, Inc. - Super League Enterprise, Inc. announced a $10 million strategic equity investment from Evo Fund, leading to a sharp increase in its stock price [1] - Shares of Super League Enterprise rose 200% to $9.83 in pre-market trading following the announcement [1] Group 2: Other Notable Gainers - Professional Diversity Network, Inc. gained 88.8% to $5.40 in pre-market trading after a previous rise of around 4% [4] - STRATA Skin Sciences, Inc. rose 80% to $3.06 in pre-market trading after an 8% increase on Monday [4] - Jiuzi Holdings, Inc. jumped 50.9% to $1.69 in pre-market trading after a 5% gain on Monday [4] - New Era Energy & Digital, Inc. gained 47.2% to $0.8941 in pre-market trading after a surge of around 12% on Monday [4] - Better Home & Finance Holding Company increased by 30% to $64.95 in pre-market trading, following a 46% jump on Monday [4] - MicroCloud Hologram Inc. surged 29% to $7.17 in pre-market trading after announcing a breakthrough in quantum technology [4] - Cassava Sciences, Inc. rose 24.1% to $2.88 in pre-market trading after CEO Richard Barry purchased shares at an average price of $2.25 [4] - SES AI Corporation surged 10.3% to $2.04 in pre-market trading after a 17% increase on Monday [4] - Ballard Power Systems Inc. gained 8.3% to $3.12 in pre-market trading after a 5% rise on Monday [4] Group 3: Notable Decliners - Psyence Biomedical Ltd. dipped 19.6% to $3.65 in pre-market trading after a decline of around 5% on Monday [4] - Diginex Limited shares fell 17.7% to $14.60 in pre-market trading after a jump of over 30% on Monday [4] - Addentax Group Corp. declined 16.5% to $0.9021 in pre-market trading after gaining more than 30% on Monday [4] - Boxlight Corporation fell 15.5% to $4.03 in pre-market trading after a significant jump of 205% on Monday [4] - Reliance Global Group, Inc. dropped 15.5% to $0.9122 in pre-market trading after a 47% increase on Monday [4] - Qualigen Therapeutics, Inc. declined 14.1% to $4.75 in pre-market trading after a 95% jump on Monday [4] - Fly-E Group, Inc. fell 13.1% to $0.8773 in pre-market trading after announcing a securities purchase agreement [4] - Firefly Aerospace Inc. dropped 12.5% to $43.29 in pre-market trading after reporting a second-quarter loss [4] - Opendoor Technologies Inc. dipped 6.3% to $7.85 in pre-market trading after a 12% fall on Monday [4] - Symbotic Inc. fell 4.8% to $57.80 in pre-market trading after a gain of more than 6% on Monday [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - 89bio, Inc. (ETNB) increased by 83% to $14.84 [3] - Aptevo Therapeutics Inc. (APVO) rose by 75% to $2.47 [3] - Psyence Biomedical Ltd. (PBM) saw a 29% increase to $4.82 [3] - Beam Global (BEEM) gained 27% reaching $3.23 [3] - MicroAlgo Inc. (MLGO) was up 14% at $13.06 [3] - Akero Therapeutics, Inc. (AKRO) increased by 12% to $47.50 [3] - Hyperion DeFi, Inc. (HYPD) rose by 11% to $13.69 [3] - Sonnet BioTherapeutics Holdings, Inc. (SONN) increased by 11% to $7.85 [3] - FuelCell Energy, Inc. (FCEL) was up 9% at $8.34 [3] - Robo.ai Inc. (AIIO) gained 6% to $2.05 [3] Premarket Losers - Presidio Property Trust, Inc. (SQFT) decreased by 14% to $7.58 [4] - Aeluma, Inc. (ALMU) fell by 10% to $15.18 [4] - FGI Industries Ltd. (FGI) dropped 10% to $7.65 [4] - Lazydays Holdings, Inc. (GORV) was down 9% at $2.26 [4] - StableX Technologies, Inc. (SBLX) decreased by 8% to $5.40 [4] - Artelo Biosciences, Inc. (ARTL) fell by 8% to $4.48 [4] - SciSparc Ltd. (SPRC) decreased by 8% to $4.10 [4] - Cracker Barrel Old Country Store, Inc. (CBRL) was down 7% at $45.75 [4] - Columbus Circle Capital Corp I (BRR) fell by 7% to $9.42 [4] - Visionary Holdings Inc. (GV) decreased by 7% to $2.58 [4]

Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company focused on developing nature-derived psilocybin and ibogaine therapies for unmet mental health needs [5] - It is the first life sciences biotechnology company specializing in psychedelic-based therapeutics to be listed on Nasdaq [5] - The company aims to address unmet mental health needs, particularly in palliative care, through an evidence-based approach [5] Upcoming Events - Psyence BioMed will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8–10, 2025 [1][9] - Dr. Neil Maresky, CEO of Psyence BioMed, will discuss the company's business strategy and pipeline during the conference [2] - A webinar for investors and shareholders is scheduled for September 16, 2025, featuring members of the Scientific Advisory Board [4] Strategic Positioning - The company emphasizes its unique operational footprint in Africa and commitment to clinical excellence as key differentiators in the psychedelic medicine sector [3] - Psyence BioMed aims to engage with global investors to highlight its differentiated approach in the industry [3]